Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
University of California, Los Angeles · Massachusetts General Hospital · +23 more institutions
Abstract
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ breast cancer, who had disease progression on endocrine therapy, for whom endocrine therapy was unsuitable, and had received one to two previous lines of chemotherapy in the inoperable/metastatic setting, were randomly assigned 1:1 to Dato-DXd (6 mg/kg once every 3 weeks) or ICC…
Citation impact
- FWCI
- 32.09
- Percentile
- 100%
- References
- 29
Authors
201- ABAditya BardiaCorresponding
University of California, Los Angeles, Massachusetts General Hospital
- KJKomal Jhaveri
Memorial Sloan Kettering Cancer Center, Cornell University
- SISeock‐Ah Im
Seoul National University Hospital
- SPSònia Pernas
Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia
- MDMichelino De Laurentiis
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Topics & keywords
- Medicine
- Vinorelbine
- Internal medicine
- Metastatic breast cancer
- Oncology
- Chemotherapy
- Eribulin
- Gemcitabine
- Good health and well-being